GSK executive buys ADS under pension plan

GSK plc filed a report describing a small insider share purchase.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

GSK plc filed a report describing a small insider share purchase. Chief People Officer Diana Conrad acquired American Depositary Shares under a GSK pension plan. She bought 12.430 ADS at a price of $54.4100 per ADS on 2026-03-16 on the New York Stock Exchange.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GSK (GSK) report in this filing?

GSK reported that Chief People Officer Diana Conrad acquired American Depositary Shares under a company pension plan. She bought 12.430 ADS at $54.4100 each, and the transaction took place on March 16, 2026 on the New York Stock Exchange.

Who is the GSK (GSK) executive involved in the March 2026 ADS transaction?

The transaction involved Diana Conrad, GSK’s Chief People Officer. She acquired 12.430 American Depositary Shares under a GSK pension plan at a price of $54.4100 per ADS, according to the March 2026 report of foreign private issuer.

How many GSK (GSK) American Depositary Shares were acquired and at what price?

The filing states that 12.430 GSK American Depositary Shares were acquired. The price per ADS was $54.4100. This was a single aggregated transaction reported as an acquisition under a GSK pension plan by Chief People Officer Diana Conrad.

On what date and exchange did the GSK (GSK) ADS acquisition occur?

The acquisition occurred on March 16, 2026. The American Depositary Shares were traded on the New York Stock Exchange, identified by the venue code XNYS, as detailed in the transaction disclosure for GSK’s Chief People Officer.

What was the nature of the GSK (GSK) transaction reported for Diana Conrad?

The transaction was described as an acquisition of American Depositary Shares under a GSK pension plan. It involved a single transaction in which 12.430 ADS were purchased at $54.4100 each, reflecting a routine benefit-related share acquisition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 12:50 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS under GSK pension plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$54.4100	12.430

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-03-16
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: March 18, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR